论文部分内容阅读
AIM:To investigate the association between cytochromeP450 2C19 (CYP2C19) gene polymorphism and cancersusceptibility by genotyping of CYP2C19 poor metabolizers(PNs) in cancer patients.METHODS:One hundred and thirty-five cases of esophaguscancer,148 cases of stomach cancer,212 cases of lungcancer,112 cases of bladder cancer and 372 controls weregenotyped by allele specific amplification-polymerase chainreaction (ASA-PCR) for CYP2C19 PMs.The frequencies ofPMs in cancer groups and control group were compared.RESULTS:The frequencies of PMs of CYP2Clg were 34.1%(46/135) in the group of esophagus cancer patients,31.8%(47/148) in the stomach cancer patients,34.4%(73/212) inthe group of lung cancer patients,only 4.5%(5/112) in thebladder cancer patients and 14.0%(52/372) in control group.There were statistical differences between the cancer groupsand control group (esophagus cancer,x~2=25.65,P<0.005,OR=3.18,95%CI=2.005-5.042;stomach cancer,x~2=21.70,P<0.005,OR=2.86,95% CI=1.820-4.501;lung cancer,x~2=33.58,P<0.005,OR=3.23,95% CI=1.503-6.906;bladdercancer,x~2=7.50,P<0.01,OR=0.288,95% CI=0.112-0.740).CONCLUSION:CYP2C19 PMs have a high incidence ofesophagus cancer,stomach cancer and lung cancer,converselythey have a low incidence of bladder cancer.It suggests thatCYP2C19 may partidpate in the activation of procarcinogen ofesophagus cancer,stomach cancer and lung cancer,but mayinvolve in the detoxification of carcinogens of bladder cancer.
AIM: To investigate the association between cytochrome P450 2C19 (CYP2C19) gene polymorphism and cancers susceptibility by genotyping of CYP2C19 poor metabolizers (PNs) in cancer patients. METHODS: One hundred and thirty-five cases of esophaguscancer, 148 cases of stomach cancer, 212 cases of Lungcancer, 112 cases of bladder cancer and 372 controls were genotyped by allele specific amplification-polymerase chain reaction (ASA-PCR) for CYP2C19 PMs. The frequencies of PMs in cancer groups and control group were compared .RESULTS: The frequencies of PMs of CYP2Clg were 34.1% (46/135) in the group of esophagus cancer patients, 31.8% (47/148) in the stomach cancer patients, 34.4% (73/212) inthe group of lung cancer patients, only 4.5% (5/112) in thebladder cancer patients and 14.0% (52/372) in control group. There were statistical differences between the cancer groups and control group (esophagus cancer, x ~ 2 = 25.65, P <0.005, OR = 3.18, 95% CI = 2.005-5.042; stomach cancer, x ~ 2 = 21.70, P <0.005, OR = 2.86, 95% CI = 1.820-4.501; P <0.005, OR = 3.23, 95% CI = 1.503-6.906; bladdercancer, x ~ 2 = 7.50, P <0.01, OR = 0.288, 95% CI = 0.112-0.740) : CYP2C19 PMs have a high incidence of esophagus cancer, stomach cancer and lung cancer, conversely have a low incidence of bladder cancer. It suggests that CYP2C19 may partidpate in the activation of procarcinogen of esophagus cancer, stomach cancer and lung cancer, but may in volume of the detoxification of carcinogens of bladder cancer.